Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

IMMUNOGENOMICS

Mutagenic exposures shape immunotherapy responses

Nature Cancer volume 1, pages 1132–1133 (2020)Cite this article

Subjects

The response to immunotherapy has been linked to human leukocyte antigen (HLA) genotype in certain cancers. A new study examining the interaction between cancer type–specific mutational exposures and the B44 and B27 HLA supertypes finds that patients with mutant peptides complementary to these supertypes receive the most benefit from immune-checkpoint blockade.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Charged HLA-B supertypes bind mutant proteins for which specific tumor types are enriched.

References

  1. Schumacher, T. N., Scheper, W. & Kvistborg, P. Annu. Rev. Immunol. 37, 173–200 (2019).

    Article  CAS  Google Scholar 

  2. Vinay, D. S. et al. Semin. Cancer Biol. 35, S185–S198 (2015).

    Article  Google Scholar 

  3. Chowell, D. et al. Science 359, 582–587 (2018).

    Article  CAS  Google Scholar 

  4. Arora, S. et al. Adv. Ther. 36, 2638–2678 (2019).

    Article  Google Scholar 

  5. Sidney, J., Peters, B., Frahm, N., Brander, C. & Sette, A. BMC Immunol. 9, 1 (2008).

    Article  Google Scholar 

  6. McGranahan, N. et al. Cell 171, 1259–1271.e11 (2017).

    Article  CAS  Google Scholar 

  7. Alexandrov, L. B. et al. Nature 500, 415–421 (2013).

    Article  CAS  Google Scholar 

  8. Alexandrov, L. B. et al. Science 354, 618–622 (2016).

    Article  CAS  Google Scholar 

  9. Cummings, A. L. et al. Nat. Cancer https://doi.org/10.1038/s43018-020-00140-1 (2020).

    Article  Google Scholar 

  10. Negrao, M. V. et al. J. Thorac. Oncol. 14, 1021–1031 (2019).

    Article  CAS  Google Scholar 

  11. Capietto, A.-H. et al. J. Exp. Med. 217, e20190179 (2020).

    Article  Google Scholar 

  12. Pham, T. V. et al. Mol. Oncol. 14, 1680–1694 (2020).

    Article  CAS  Google Scholar 

  13. Wood, M. A., Weeder, B. R., David, J. K., Nellore, A. & Thompson, R. F. Genome Med. 12, 33 (2020).

    Article  CAS  Google Scholar 

  14. Cabrera, T. et al. Hum. Immunol. 64, 941–950 (2003).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biomedical Informatics Program, University of California San Diego, La Jolla, CA, USA

    Andrea Castro

  2. Department of Medicine, Division of Medical Genetics and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA

    Andrea Castro & Hannah Carter

Authors
  1. Andrea Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hannah Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hannah Carter.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Castro, A., Carter, H. Mutagenic exposures shape immunotherapy responses. Nat Cancer 1, 1132–1133 (2020). https://doi.org/10.1038/s43018-020-00153-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-020-00153-w

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer